Claims As Of 7-10-2002

27. A composition comprising a fatty acid-acylated insulin and zinc.

28. A composition comprising an aqueous solution of a fatty acid-acylated insulin and zinc.

29. The composition of Claim 28, wherein the solution comprises about 0.2 mole to about 0.7 mole of zinc per mole of fatty acid-acylated insulin.

30. The composition of Claim 29, wherein the pH is 6.8 to 7.8.

31. (Once Amended) The composition of Claim 30, further comprising a phenolic compound at a concentration of from 0.5 mg to 5 mg per milliliter of the aqueous solution.

32. The composition of Claim 31, wherein the fatty acid-acylated insulin is N-acylated Lys^{B29} human insulin.

57. The composition of claim 28, wherein the composition is a pharmaceutical composition that further comprises a phenolic compound, glycerol, and a pharmaceutically acceptable buffer.

58. The composition of Claim 27, wherein the composition comprises about 0.2 mole to about 0.7 mole of zinc per mole of fatty acid-acylated insulin.

59. The composition of Claim 58, wherein the pH is 6.8 to 7.8.

60. The composition of Claim 27, wherein the fatty acid-acylated insulin is N-acylated Lys^{B29} human insulin.

61. The composition of claim 32, wherein the fatty acid-acylated insulin is N-palmitoyl Lys^{B29} human insulin, and wherein the solution comprises from about 0.3 mole to about 0.55 mole of zinc per mole of fatty acid-acylated insulin.

62. The composition of claim 61, wherein the concentration of phenolic compound is from about 2.5 mg to about 5.0 mg per milliliter of the aqueous solution.

63. The composition of claim 62, wherein the phenolic compound is selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, methylparaben, and mixtures thereof.

64. The composition of claim 63, wherein the phenolic preservative is selected from the group consisting of phenol and m-cresol.